Navigation Links
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
Date:12/6/2008

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, will be presented in a press conference on Saturday, December 6, at 8:00 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. The studies featured in the press conference will report on a new combination therapy for previously untreated idiopathic thrombocytopenic purpura (ITP), an investigational oral treatment for chronic ITP, a low-dose platelet transfusion strategy for patients with hypoproliferative thrombocytopenia, and a new therapeutic platelet transfusion approach following high-dose chemotherapy and autologous stem cell transplantation.

"We have some very exciting data on novel therapeutic approaches to minimize bleeding episodes in patients with platelet disorders," said press conference moderator Kenneth Kaushansky, MD, 2008 President of the American Society of Hematology and Helen M. Ranney Professor and Chair of the Department of Medicine at the University of California, San Diego School of Medicine. "The results of these studies will likely transform the way hematologists treat and manage these conditions, ultimately resulting in improvements in overall patient outcomes such as reducing bruising and unnecessary bleeding that can result if left untreated."

Types of thrombocytopenia, a blood disorder with 50 to 150 new cases per 1 million people each year, are typically classified by one of three causes: low production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream, or increased breakdown of platelets in the spleen or liver, which can be induced by certain anemias, cancers, infections, or medications. Symptoms can include bruising, nose bleeds, bleed
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...wire/--The2009Frost&SullivanSouthAfricaCompany...esentedtoCiplaMedproSouthAfricaLimited. ,, (Log...LOGO ) ,, FortheCompanyoftheYearAward,thefollow...anceagainstkeycompetitors:growthstrategyandimpleme...uctsand/ortechnologiesandleadershipincustomervalue...
(Date:11/25/2009)...PraxisElectronicMedicalRecordsreceivedfirstplacera...)FamilyPracticeManagement(FPM)2009EHRUserSatisfact...nce,anddiseasemanagement,allcriticalfornewARRAStim...catingtheirEMRhadapositiveeffectindeterminingtheir...ryinprovidingexcellenttrainingandsupport.Intheprev...
(Date:11/25/2009)...all/--AmericanScientificResourcesInc.(PinkSheets:A...penedaregionalmarketingandproductionmanagementoffi...ocationabroad,providinganessentialgatewayforthedev...fetyproductsforchildrenandadultstobedistributedand...hestateofOhiowheretheywillalsobeabletodosubcompone...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2American Scientific Resources Inc. Opens Shanghai Location 2Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference 53844 1Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference 53844 2Global Health Trax Inc Announces New Marketing Campaign for Oxygen Elements Max Product 53842 1Global Health Trax Inc Announces New Marketing Campaign for Oxygen Elements Max Product 53842 2InfoLogix Selected by Hilo Medical Center for Multi Year Engagement to Deliver Wireless as a Service 53837 1InfoLogix Selected by Hilo Medical Center for Multi Year Engagement to Deliver Wireless as a Service 53837 2InfoLogix Selected by Hilo Medical Center for Multi Year Engagement to Deliver Wireless as a Service 53837 3
..., a bioMerieux company,that discovers, develops an...,oncology, reported today findings from three stud...say to predict risk of disease recurrence in,indiv...ed this week at the San,Antonio Breast Cancer Symp...dex(SM) (BCI) is a combination of Theros,H/I(SM) (...
...ta from two early,clinical studies show that RAD00...ptin(R) (trastuzumab)* in women with HER2-positive...he initiation of a Phase III clinical trial,progra...ed brand name,Afinitor(R)) in breast cancer. , ... the CTRC-AACR San Antonio,Breast Cancer Symposium...
Other Medicine Technology:Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 2RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 3RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 4RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 5RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 6RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 7
(Date:11/25/2009)...inelleMedicalInc.,aleadingmanufacturerofbreastMRIc...ofnewleadingedgeclinicalapplicationsonitsAegis(TM)...icalSocietyofNorthAmerica(RSNA)annualmeetinginChic...ionsleveragetheuniquehighqualityimagesgeneratedbyS...tipleimagingmodalitiesformulti-parametricassessmen...
(Date:11/25/2009)...--TheBayAreaAirQualityManagementDistrictisissuingt...lert forThursday,November26,2009whichbansburning...ndoorsandoutdoors. ,, "Cold,stillweatherwillcon...dbent,executiveofficeroftheAirDistrict."We,reaskin...sandfellowcommunitymembersthisThanksgiving,andnott...
(Date:11/25/2009)...t of a collaboration between UCLA engineers and ph...y 10 million Americans who suffer from peripheral ...of the arteries, peripheral arterial disease, or P...wed arteries reduce blood flow to the limbs. The c...ease, heart attack and stroke, and its progression...
(Date:11/25/2009)...d treatment clinics to resume Monday, Nov. 30 , ...25, 2009 -- Centegra Health System is continuing t... at four Centegra Primary Care (CPC) vaccination c...ed. The clinics are at CPC sites in Huntley, Woods... follows: ,   From 4:30 to 7:30 p.m. T...
(Date:11/25/2009)...SSIONSkincare ®isproudtosupportGNC,seffortsto...alSt.Jude ThanksandGiving campaign,$1fromthepurcha...LipBalm willbedonatedtoSt.Jude.Additionally,GNCcus...tcheckoutatoneoftheir5,000+retaillocationsoratGNC....ngtheir2009 ThanksandGiving campaign. ,, "Weare...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
...., MARCH 17, 2009 The medical costs that business...ould cover the costs for nearly a dozen healthy, f... the March of Dimes. , The average medical cost ..., according to the new data. For premature and/or ...
... Fla., March 16 eDiets.com, Inc. (Nasdaq: DIET ...fitness and healthy lifestyle solutions, today ann...onths ended December 31, 2008. , , Revenues for t...hare, for the fourth quarter of 2008 compared to $...
...TING, Pa., March 16 /PRNewswire-Asia-FirstCall/ --...Sunstone", "we" or the "Company"),today announced ...0.0% Secured,Promissory Notes due May 1, 2009 (the...ount 10.0% senior secured, promissory notes ...
...alif., March 16 The Ensign Group, Inc. (Nasdaq: ...p of skilled nursing, rehabilitative care services...at its Board of Directors has declared a quarterly...has been a dividend-paying company since 2002. , ...
...ke tough choice on whether it,s worthwhile, expert...) -- Implanted defibrillators don,t seem to provi...t failure, a new study finds. , A defibrillator ca...gressive loss of the heart,s ability to pump blood...
...us the nation is getting fatter, and that obesity ...tory, according to one University of Houston socio...een a shift in body weight over the years, assista...n says. And the use of the Body Mass Index, which ...
Other Medicine News:Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3Health News:eDiets.com(R) Announces Q4 2008 Results 2Health News:eDiets.com(R) Announces Q4 2008 Results 3Health News:eDiets.com(R) Announces Q4 2008 Results 4Health News:eDiets.com(R) Announces Q4 2008 Results 5Health News:eDiets.com(R) Announces Q4 2008 Results 6Health News:eDiets.com(R) Announces Q4 2008 Results 7Health News:BMP Sunstone Exchanges and Calls Outstanding Notes Due May 2009 2Health News:Defibrillator May Not Help Many With Heart Failure 2Health News:Defibrillator May Not Help Many With Heart Failure 3Health News:UH sociologist has different perspective on obesity 'epidemic' 2Health News:UH sociologist has different perspective on obesity 'epidemic' 3
USA Elite System™ Visual Urethrotome
USA Elite System™ Visual Urethrotome Kit
Classic Series™ Otis Urethrotome
...-2000 Flexible Cystoscope with Slide-On EndoSheath...ue and efficient solution for Urologists in both t...conventional flexible cystoscopes, which require r...-2000 eliminates the need to reprocess between eve...
Medicine Products: